Long-Term Outcomes of Anti-Vascular Endothelial Growth Factor Therapy for Polypoidal Choroidal Vasculopathy

Chang, Young Suk; Kim, Jae Hui; Kim, Kyung Min; Kim, Jong Woo; Lee, Tae Gon; Kim, Chul Gu; Cho, Sung Won

doi:10.1089/jop.2015.0073

Cited by 12 publications

(8 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Since long-term follow-up is difficult in ordinary clinical practice, the number of patients in each treatment group among various subtypes of PCV is relatively small, so that our results might need to be confirmed by further studies which include more subjects. Although we have examined the distribution of various treatment regimens among different subtypes of PCV, bias due to the small number of subjects seems to be unavoidable in such a study, which is similar to previous studies of long-term treatment for PCV [11][12][13][14][15][16]. Moreover, because of the retrospective nature of this study, long-term randomized clinical trials and prospective real-world studies are needed to investigate more effective treatment regimens for PCV according to imaging features.…”

Section: Discussionsupporting

confidence: 64%

“…e discontinuity of ELM, EZ, or RPE was defined as a disruption of the corresponding line or band on OCT images. Because ICGA was an invasive examination and was not considered to be performed routinely in clinical practice during follow-up, the recurrence of fluid and exudation was defined as the recurrence of disease activity using OCT [13].…”

Section: Examinationmentioning

confidence: 99%

“…Unlike clinical trials which enrolled subjects with restrict criteria prospectively, the efficacy of these treatment regimens needs to be confirmed in real world. Several studies have confirmed the efficacy of anti-VEGF therapies and PDT with additional anti-VEGF therapy for PCV over a long-term period [11][12][13][14][15][16]. However, long-term outcomes of initial combination therapy of PDT and anti-VEGF therapy in real world have not been reported.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Six-Year Real-World Outcomes of Antivascular Endothelial Growth Factor Monotherapy and Combination Therapy for Various Subtypes of Polypoidal Choroidal Vasculopathy

Yang

Yuan

Song

et al. 2019

Journal of Ophthalmology

View full text Add to dashboard Cite

The purpose of this study was to compare 6-year visual outcomes of antivascular endothelial growth factor (anti-VEGF) monotherapy and initial combination therapy of photodynamic therapy (PDT) and anti-VEGF therapy for polypoidal choroidal vasculopathy (PCV) in a Chinese population and to investigate imaging biomarkers associated with visual outcomes. Forty-eight treatment-naive PCV eyes of 46 patients were reviewed retrospectively, which underwent anti-VEGF monotherapy or initial combination therapy. PCV was classified into 2 subtypes. Mean best-corrected visual acuity (BCVA) using logarithm of minimal angle resolution and imaging morphological features was compared. No significant differences of mean BCVA changes were noticed between anti-VEGF monotherapy and combination therapy in either subtype 1 PCV or subtype 2 PCV during 6-year period (all P values >0.05). Compared with BCVA at baseline, the mean BCVA at 72 months deteriorated significantly in eyes with subtype 1 PCV (P<0.001), while the mean BCVA at 72 months remained stable in eyes with subtype 2 PCV (P=0.941). In subtype 2 PCV eyes with continuous retina pigment epithelium, the mean changes of BCVA in eyes treated with anti-VEGF monotherapy were better than those in eyes treated with combination therapy (P=0.020). Anti-VEGF monotherapy and combination therapy for various subtypes of PCV had comparable long-term visual outcomes in most cases in real world. Imaging biomarkers which correlate with visual outcomes and treatment response should be included in the classification of PCV and validated in real world.

show abstract

Section: Discussionsupporting

confidence: 64%

Section: Examinationmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Six-Year Real-World Outcomes of Antivascular Endothelial Growth Factor Monotherapy and Combination Therapy for Various Subtypes of Polypoidal Choroidal Vasculopathy

Yang

Yuan

Song

et al. 2019

Journal of Ophthalmology

View full text Add to dashboard Cite

show abstract

“…Therefore, our subjects had a markedly lower injection frequency than that of previous studies. Second, baseline visual acuity was predictive of long-term visual outcome in eyes with PCV [30,31]. Because our patients had a good baseline visual acuity, regardless of polyp location, this may have influenced our visual outcomes.…”

Section: Discussionmentioning

confidence: 92%

Two-year Outcomes after Intravitreal Anti-vascular Endothelial Growth Factor Therapy for Polypoidal Choroidal Vasculopathy Patients with Good Initial Visual Acuity

Yoo

Kim

Han

et al. 2017

J Retin

Self Cite

View full text Add to dashboard Cite

Purpose:To investigate 2-year treatment outcomes of anti-vascular endothelial growth factor (VEGF) therapy in eyes with polypoidal choroidal vasculopathy (PCV) with good baseline visual acuity. Methods: This retrospective, observational study included 21 eyes (10 eyes with a subfoveal polyp, 11 eyes with an extrafoveal polyp) of 21 subjects diagnosed with PCV. All eyes had a baseline best-corrected visual acuity (BCVA) of 20/25 or better and were administered an initial treatment of three intravitrial anti-VEGF injections at one-month intervals. Additional anti-VEGF treatments were administered as needed for recurring cases. BCVA and central foveal thickness (CFT) obtained 24 months after diagnosis were compared with baseline values. Results: Mean logarithm of the minimal angle of resolution (logMAR) BCVA was 0.07 ± 0.04 at baseline and 0.19 ± 0.29 approximately 24 months after initial diagnosis, a slight difference that was not statistically significant (p = 0.560). Of the 21 eyes included, 17 eyes (80.9%) had stable vision and 4 eyes (19.0%) had a ≥0.2 deterioration in logMAR BCVA. Twenty-four-month CFT (212.9 ± 76. 1 µm) was significantly lower than baseline CFT (324.6 ± 121.2 µm, p = 0.015). Conclusions: Two-year visual outcomes following anti-VEGF therapy in eyes with PCV and good initial visual acuity were generally favorable. However, logMAR BCVA deteriorated by ≥0.2 in 19.0% of treated eyes.

show abstract

“…Kang et al reported an improved visual outcome from a mean baseline BCVA of 0.78 logMAR to the 5-year BCVA of 0.67 logMAR in 42 PCV eyes treated with PDT [17]. On the contrary, unfavorable visual acuity was also detected in another study reported Chang et al They retrospectively evaluated the 4-year treatment outcome of 31 PCV eyes treated with anti-VEGF therapy [15]. The mean visual acuity at baseline was 0.52 logMAR and after 4 years was 0.83 logMAR.…”

Section: Discussionmentioning

confidence: 99%

Five-year real-world outcomes of anti-vascular endothelial growth factor monotherapy versus combination therapy for polypoidal choroidal vasculopathy in a Chinese population: a retrospective study

et al. 2019

View full text Add to dashboard Cite

BackgroundTo evaluate 5-year outcomes of anti-vascular endothelial growth factor (VEGF) monotherapy and combination therapy of anti-VEGF agents and photodynamic therapy (PDT) for polypoidal choroidal vasculopathy (PCV) in a real-world Chinese population.MethodsRetrospective study. Fifty-three eyes of 46 patients with subtype 1 and 2 PCV followed up for at least 60 months were grouped into three regimens: anti-VEGF monotherapy, PDT combining with anti-VEGF therapy initially, and PDT combining with deferred anti-VEGF therapy. Main outcome measure was best-corrected visual acuity (BCVA) using logarithm of minimal angle of resolution (logMAR).ResultsThe mean BCVA of eyes with subtype 1 PCV (n = 28) deteriorated from 0.69 logMAR at baseline to 1.25 logMAR at months 60 (P = 0.001), while the mean BCVA of eyes with subtype 2 PCV (n = 25) sustained stable from 0.62 logMAR at baseline to 0.57 at months 60 (P = 0.654). No significant differences of visual outcomes were found between the 3 treatment regimens for subtype 1 PCV. Anti-VEGF monotherapy and initial combination treatment had better visual outcomes in eyes with subtype 2 PCV than deferred combination group during part of follow-up significantly. Initial combination group needed a less number of PDT than deferred combination group (P < 0.001).ConclusionsCompared with subtype 1 PCV, subtype 2 PCV has a more favorable visual outcome in real world. All the regimens presented unfavorable visual outcomes for subtype 1 PCV. Anti-VEGF monotherapy and initial combination therapy should be superior to deferred combination therapy in the long-term management of subtype 2 PCV. Prospective randomized studies of larger size are needed to determine the long-term efficacy and safety of various treatment for PCV in real world.

show abstract

Long-Term Outcomes of Anti-Vascular Endothelial Growth Factor Therapy for Polypoidal Choroidal Vasculopathy

Abstract: Although the long-term treatment outcome of PCV is generally unfavorable, stable vision can be achieved in approximately half of the patients. Visual acuity at 12 months after the initial treatment is predictive of long-term visual outcomes.

Cited by 12 publications

References 23 publications

Six-Year Real-World Outcomes of Antivascular Endothelial Growth Factor Monotherapy and Combination Therapy for Various Subtypes of Polypoidal Choroidal Vasculopathy

Six-Year Real-World Outcomes of Antivascular Endothelial Growth Factor Monotherapy and Combination Therapy for Various Subtypes of Polypoidal Choroidal Vasculopathy

Two-year Outcomes after Intravitreal Anti-vascular Endothelial Growth Factor Therapy for Polypoidal Choroidal Vasculopathy Patients with Good Initial Visual Acuity

Five-year real-world outcomes of anti-vascular endothelial growth factor monotherapy versus combination therapy for polypoidal choroidal vasculopathy in a Chinese population: a retrospective study

Contact Info

Product

Resources

About